🇺🇸

US SEC Filing Intelligence

· daily

US Corporate Board Director Changes SEC Filings — April 23, 2026

Across 35 SEC filings on USA Board Room Changes dated April 23, 2026, a dominant theme is proactive board and C-suite strengthening, with 18 positive appointments/promotions in biotech/healthcare (e.g., Indaptus, BridgeBio, Vaxart), financials (BayCom, Franklin Financial), and industrials/utilities (Edison, RPM, Avantor), signaling management conviction in growth amid clinical expansions and operational efficiencies. Financial reporters like Texas Capital Bancshares (NI +63% YoY to $69.5M despite -28% QoQ), Cass Information (+26.9% adj EPS YoY), SES AI (revenue +47% QoQ to $6.7M), and Acadia (guidance reaffirmed) show mixed Q1 trends: YoY improvements in diversification/NIM but QoQ pressures from credit losses and mix shifts. Resignations/retirements in 14 filings (e.g., Exagen, Burzynski CFO, Zura Bio CFO) were mostly neutral without disagreements, often with quick internal promotions, reducing disruption risks. Capital allocation trends favor shareholders: Texas Capital initiates first $0.20 dividend, Cass $0.32 dividend +64k share buyback, Charter approves 16M share incentive increase post-95-99% director elections. Portfolio-level: Banks (5/35) average +30% YoY NI growth but rising provisions/non-accruals (e.g., Texas Cap +YoY criticized loans); biotechs show clinical catalysts. Implications: Bullish for leadership-upgraded firms pre-earnings; watch CFO churn (7 cases) for execution risks.

35 high priority 35 total filings
· daily

US Merger & Acquisition SEC Filings — April 23, 2026

The 9 filings reveal a vibrant SPAC and M&A landscape on April 23, 2026, dominated by lifecycle extensions (4/9 companies), asset acquisitions (3/9), PIPE financings, and one high-profile liquidation, signaling persistent deal-making amid deadline pressures. Positive sentiments prevail in 4/9 cases, driven by data center buys, sports betting acquisitions, and $32M recycling PIPE, contrasting ESH's dissolution; no broad YoY revenue/margin trends emerge, but capital inflows via trust deposits ($125k-$50k notes) and share issuances highlight liquidity support for combos. Insider conviction shines in Cayson deposits and promissory notes, with forward-looking catalysts clustering in May-June 2026 closings/extensions to 2027. Portfolio-level pattern: 6/9 SPACs actively extending/pursuing targets, implying sector resilience but elevated liquidation risk (1/9 materialized). Market implications include alpha in pre-close assets (e.g., 3MW data center) and PIPE-backed mergers, while monitoring governance shifts in Motorsport/Day One for takeover confirmations. Overall, M&A activity skews bullish for tech/data/recycling niches, with extensions buying time versus outright failures.

9 high priority 9 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 23, 2026

Across 50 overnight SEC filings for April 22-23, 2026, Q1 2026 earnings dominate with mixed results: 18/25 reporters showed YoY revenue growth averaging +12% (e.g., Tesla +16%, Thermo Fisher +6%, ServiceNow +22%), but QoQ declines in 14 cases (e.g., Helix -14%, Patterson -2.9%) amid seasonal and pricing pressures; margins compressed in 9/15 (avg -80 bps) due to impairments/expenses. Capital allocation emphasizes shareholder returns with Netflix's $25B buyback (adding to $6.8B remaining), Thermo Fisher $3B repurchases +10% dividend hike, Packaging record shipments, and banks like Texas Capital initiating $0.20 dividend. Positive M&A/deals (L3Harris $1B DoD investment, Coeur 96% note exchange, CVB Heritage acquisition) contrast risks like Waste Connections impairments surging to $79.6M (+1136% YoY). Utilities (CenterPoint +6% NI, PG&E +37%) outperform energy services (Liberty EBITDA -25% YoY), signaling sector rotation potential. Forward guidance steady (Honeywell, PG&E, CenterPoint reaffirmed), with April 23 calls as key catalysts; biotech/healthcare positives (Nektar $325M raise, Gentherm +7.2% revenue) highlight growth pockets amid broader caution on credit provisions in banks (avg +20% YoY).

26 high priority 24 medium 50 total filings
· daily

Biotech Small-Cap Approvals — April 22, 2026

The April 22, 2026 period (Biotech Small-Cap Approvals stream) featured 5 Other approvals (0 NMEs, 0 biosimilars, 0 label expansions), all with neutral signals (strength and materiality 5/10). No dominant therapeutic area theme emerged, as approvals spanned diabetes/cardiorenal (CANAGLIFLOZIN), pulmonary fibrosis (PIRFENIDONE), electrolytes (SODIUM ACETATE), ophthalmology (BRIMONIDINE TARTRATE), and pulmonary hypertension (SELEXIPAG). Highest-conviction signal is AUROBINDO PHARMA's dual biosimilar approvals for CANAGLIFLOZIN and PIRFENIDONE, signaling regulatory execution for this small-cap sponsor though peak sales, exclusivity, pricing, and market position are NOT_DISCLOSED. Key risk/watch item is post-approval launch execution and competitive market entry for these entrants amid NOT_DISCLOSED commercial details.

5 total filings
· daily

Big Pharma Approvals — April 22, 2026

The April 22, 2026 period features 2 FDA approvals in the Big Pharma stream, with a mix of 0 NMEs, 0 biosimilars, 0 label expansions, and 2 others, both bullish signals for NOVARTIS PHARMS CORP. Both approvals are fallback/other types for label expansions of SECUKINUMAB (COSENTYX), indicating incremental portfolio strengthening without new exclusivity or peak sales data disclosed. No dominant therapeutic area theme is evident from the approvals. The highest-conviction signal is the dual bullish label expansions for SECUKINUMAB by NOVARTIS PHARMS CORP, which could support sustained revenue from an established asset. Key risk/watch item: undisclosed peak sales, exclusivity, pricing power, and market position details limit quantifiable commercial impact assessment.

2 total filings
· daily

New Drug Approvals (Original) — April 22, 2026

This one-day FDA approvals window (April 16-20, 2026) delivered 5 neutral 'Other' fallback approvals (0 NMEs, 0 biosimilars per mix, 0 label expansions), all described as biosimilar approvals to lesser-known sponsors with no disclosed commercial metrics. No dominant therapeutic area theme, as approvals span diabetes (CANAGLIFLOZIN), idiopathic pulmonary fibrosis (PIRFENIDONE), electrolytes (SODIUM ACETATE), ophthalmology (BRIMONIDINE TARTRATE), and pulmonary arterial hypertension (SELEXIPAG). Highest-conviction signal is AUROBINDO PHARMA's back-to-back biosimilar approvals for CANAGLIFLOZIN and PIRFENIDONE, indicating execution strength in generics/biosimilars entry for this sponsor. These are bullish for entrants' market access but bearish for originators facing erosion risk; overall neutral per FDA signals (5/10 strength/materiality). Key risk/watch item: all peak sales, exclusivity, pricing power, and market position NOT_DISCLOSED, capping upside assessment.

5 total filings
· daily

VA Healthcare & Services Contracts — April 22, 2026

The single VA Healthcare & Services contract analyzed totals $103,954,050 in obligations, representing a fully civilian award with 0/1 defense-related, focused on Department of Veterans Affairs IT modernization via cloud operations. Cognosante MVH LLC, a subsidiary of Novetta Solutions LLC, secured this $103.9M Time and Materials Delivery Order under full and open competition, with $82.6M already outlayed since the 2023-08-09 award, signaling strong execution in VA cloud migration services. The highest-conviction bullish signal is for Novetta Solutions LLC's Tech sector exposure, estimating ~$34.7M annual revenue through 2026-08-08. A key watch item is the exercise of unobligated options toward the $186.2M ceiling, alongside monitoring $71.2M in subawards representing 86% of outlays for prime retention risk. This underscores durable VA IT spending but highlights subcontracting dependencies in civilian contracts.

1 total filings
· daily

New Federal Contractors — April 22, 2026

These four new federal contracts totaling $395,776,263 in obligations represent purely civilian agency spending (0/4 defense-related), focused on IT services, cloud migration, SaaS platforms, and space R&D across DOI, VA, USDA, and NASA. Dominant themes include civilian IT modernization with bullish signals from high-materiality awards to MAXIMUS FEDERAL CONSULTING, LLC ($106M) and COGNOSANTE MVH LLC ($104M), alongside Palantir's $95M USDA win. Highest-conviction signals are medium-term revenue stability from Time & Materials IT contracts at DOI and VA, given $106M and $104M obligations with significant outlays already. Key risk is unexercised options (e.g., MAXIMUS ceiling to $200M, COGNOSANTE to $186M) and zero outlays on Palantir's fresh $95M BPA call. Watch outlay progress and option exercises through 2026-2027 amid CR uncertainty for recent awards.

4 total filings
· daily

Significant Contract Modifications ($10M+) — April 22, 2026

Four significant civilian contract modifications totaling $395,776,263 across DOI, VA, USDA, and NASA highlight robust federal IT and R&D spending with zero defense exposure. Dominant themes include IT modernization via custom programming (Maximus $106M DOI), cloud operations (Cognosante $104M VA), SaaS platforms (Palantir $95M USDA), and space aerosols R&D (Caltech $91M NASA). Highest-conviction bullish signals center on Maximus Federal Consulting ($106M obligated, full competition) and Cognosante MVH ($104M obligated, $83M outlayed) for sustained Time & Materials IT revenue through 2026. Key risk is unexercised options limiting upside (e.g., Maximus to $200M, Cognosante to $186M) and slow outlays (Palantir at $0 of $95M).

4 total filings
· daily

Contract Deobligations Alert — April 22, 2026

Four civilian agency contracts totaling $395,776,263 in obligations signal bullish IT services momentum absent any defense exposure (0/4 defense-related). Dominant theme is civilian IT modernization across DOI, VA, USDA, and NASA, with full and open competition wins emphasizing cloud, SaaS, and custom programming. Highest-conviction bullish signals center on MAXIMUS FEDERAL CONSULTING, LLC ($106M DOI) and COGNOSANTE MVH LLC ($104M VA), both Time and Materials awards with significant outlays already ($106M and $82.6M respectively). Neutral signal on CALIFORNIA INSTITUTE OF TECHNOLOGY's $91M NASA R&D contract due to its nonprofit status and low materiality. Key risk is pending option exercises across all contracts, potentially capping revenue below ceilings like $199M for Maximus and $186M for Cognosante; watch outlay progress and subaward retention.

4 total filings
· daily

Contract Option Exercises — April 22, 2026

These four contract option exercises total $395,776,263 in obligations, entirely civilian agency awards with zero defense exposure, highlighting IT services and R&D momentum across DOI, VA, USDA, and NASA. Dominant themes include custom programming, cloud migration, SaaS platforms, and space science R&D, led by high-materiality bullish wins for MAXIMUS FEDERAL CONSULTING, LLC ($106M) and COGNOSANTE MVH LLC ($104M). Highest-conviction signals are bullish for established IT delivery orders with significant outlays already ($106M and $82.6M respectively), signaling revenue durability through 2026. Key risk is medium pricing risk under Time and Materials structures for MAXIMUS and COGNOSANTE, plus high pricing risk for Palantir's $95M firm fixed price BPA; watch option exercises toward ceilings like $199M for MAXIMUS and $186M for COGNOSANTE.

4 total filings
· daily

Federal IT & Cybersecurity Contracts — April 22, 2026

Two civilian IT contracts totaling $210,275,631 in obligations highlight steady revenue for Maximus Federal Consulting, LLC ($106.3M from Department of Interior) and Cognosante MVH LLC ($104.0M from Department of Veterans Affairs), with no defense exposure. Dominant themes are civilian agency IT support services, including DOD SAP CIO SETA via Interior and VA cloud operations/migration. Highest-conviction bullish signals stem from significant outlays ($106M fully outlayed for Maximus; $82.6M for Cognosante) and ceilings up to $386M combined including options. Key risks include medium pricing risk from Time & Materials structures and high subawards (86% of Cognosante outlays). Watch option exercises toward 2026 end dates amid uncertain outlay pacing.

2 total filings
· daily

NASA & Space Contracts Intelligence — April 22, 2026

NASA dominates this $90,812,821 civilian contract obligation (0% defense-related) to California Institute of Technology for the MAIA Multi-Angle Imager for Aerosols project, underscoring long-term space science R&D funding via a cost-plus-fixed-fee delivery order active since 2018. With $60,980,603 already outlayed out of a potential $101,500,658 including options, the neutral signal (4/10 strength) reflects limited direct equity investment implications due to the recipient being a nonprofit educational institution. The dominant agency theme is NASA Management Office -- JPL prioritizing uncompeted R&D in aerosols imaging (NAICS 541715, PSC AR22). Highest-conviction signal is neutral multi-year stability through 2028-09-30. Key watch item is outlay progress beyond $60,980,603 and exercise of options to full value.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — April 22, 2026

Two mega contracts totaling $210,275,631 in obligations highlight bullish IT services momentum for civilian agencies, with zero defense-related awards split fully to Department of the Interior and Department of Veterans Affairs. MAXIMUS FEDERAL CONSULTING, LLC secured $106.3M for DOD SAP CIO SETA support via DOI, while COGNOSANTE MVH LLC (Novetta subsidiary) won $104.0M for VA T4NG Cloud Operations, both under full and open competition with Time & Materials pricing. Highest-conviction signals are bullish revenue streams (7/10 strength) for these firms amid civilian IT modernization. Key risk is medium pricing/execution uncertainty from unexercised options ($199M and $186M ceilings) and high subawards (86% of Cognosante outlays). Watch option exercises and outlay progress toward 2026 end dates for revenue upside confirmation.

2 total filings
· daily

High-Value Federal Grants ($5M+) — April 22, 2026

Four high-value civilian federal contracts totaling $395,776,263 in obligations (0/4 defense-related) underscore IT modernization and cloud/SaaS investments across DOI, VA, USDA, and NASA. Dominant theme is civilian agency IT services, with highest-conviction bullish signals from Maximus Federal Consulting LLC's $106M DOI award for DOD SAP CIO SETA support and Cognosante MVH LLC's $104M VA cloud operations contract, both under full and open competition. Palantir Technologies Inc. secures $95M USDA BPA call for farm IT SaaS, while California Institute of Technology's $91M NASA R&D award remains neutral due to nonprofit status. Key risk: limited outlays to date (e.g., $0 for Palantir, $82.6M of $104M for Cognosante) and unexercised options capping upside.

4 total filings
· daily

General Federal Contracts — April 22, 2026

Four civilian government contracts totaling $395,776,263 in obligations highlight bullish IT services momentum across Department of the Interior, Veterans Affairs, Agriculture, and NASA, with zero defense exposure. Highest-materiality awards to MAXIMUS FEDERAL CONSULTING, LLC ($106M) and COGNOSANTE MVH LLC ($104M) under full and open competition signal durable revenue for custom programming and cloud operations through 2026. Palantir Technologies Inc. secures a $95M firm-fixed-price BPA for USDA farm IT systems, while California Institute of Technology's $91M NASA R&D award remains neutral due to its nonprofit status. Key watch item: progress on option exercises and outlays, as only partial funds are disbursed in three contracts.

4 total filings
· daily

All NASA Contracts — April 22, 2026

NASA dominates this $90,812,821 total obligation period with a single civilian contract (0/1 defense-related), focused on long-term space science R&D. The sole award to California Institute of Technology, a nonprofit, for the MAIA Multi-Angle Imager for Aerosols project carries a neutral signal (avg strength 4.0/10, materiality 3/10) with $60,980,603 already outlayed toward a $101,500,658 ceiling. Highest-conviction signal is low-risk multi-year funding continuity through 2028 for civilian space applications under NAICS 541715. Limited direct equity implications due to nonprofit recipient. Key watch item: outlay progress beyond $60,980,603 and exercise of options to reach full $101.5M value.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 22, 2026

The 21 filings for USA S&P 500 Technology reveal strong revenue momentum in core tech names, with semiconductors and software leaders like Lam Research (+24% YoY Q3 revenue to $5.84B), ServiceNow (+22% YoY subscription revenue to $3.671B), Texas Instruments (+19% YoY Q1 revenue to $4.83B), and Intuitive Surgical (+23% YoY Q1 revenue to $2.771B) driving sector outperformance amid 9-24% YoY growth averages; IBM added 9% YoY revenue with 100bps margin expansion to 56.2%. Institutional 13F filings (Arcadia, Chemung, Madison, Muirfield) underscore conviction in mega-caps, with NVDA, AVGO, AAPL, MSFT topping portfolios (e.g., Arcadia NVDA $30.8M, Broadcom $40.9M). Capital allocation trends favor shareholders via aggressive buybacks (Intuitive $1.123B Q1, ServiceNow 20.1M shares, Mueller $75M) and dividend hikes (IBM to $1.69/share, Century 10% to $0.32). Forward guidance is mostly raised (ServiceNow FY sub rev to $15.735-15.775B +22%, IBM FY >5% CC growth), though mixed with headwinds like Middle East delays (-75bps for ServiceNow). Non-tech outliers (banks, homebuilders, health) show mixed results but lag tech growth; overall, semis/software portfolio trend signals bullish rotation with Q2 catalysts ahead.

5 high priority 16 medium 21 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 22, 2026

Across 20 filings from NASDAQ-100 constituents and related entities, key themes include robust revenue growth in semiconductors (TI +19% YoY, Lam +24% YoY, Intuitive +23% YoY) contrasting with softness in homebuilding (Century -12.6% YoY) and healthcare (CHS -6.1% YoY), while Tesla showed +16% revenue amid AI advancements. Period-over-period trends reveal 6/10 earnings reporters with YoY revenue growth averaging +18%, but mixed margins (Tesla +478bp expansion vs. others flat/compressed) and strong free cash flow generation (Tesla +117%, TI FCF +154% TTM). Capital allocation remains shareholder-friendly with buybacks (Intuitive $1.12B, Century $40M, Mueller $75M, Pineapple expansion to $15M) and dividend hikes (Century +10%, TI +4% TTM), alongside 13F snapshots confirming institutional overweight in mega-caps like NVDA, AAPL, MSFT. Positive catalysts include Robotaxi launches (Tesla), Nasdaq uplisting (First Northern), and ETF splits, but risks from inventory builds (Tesla +23% days), guidance cuts (Century FY deliveries 9.5-10.5K), and reverse splits (Creative Media). Overall, semis outperform with upward guidance, signaling portfolio rotation opportunities into tech amid broader mixed sentiment.

4 high priority 16 medium 20 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 22, 2026

The 50 filings reveal a diverse snapshot dominated by ~25 neutral 13F-HR disclosures from investment managers showing heavy ETF allocations (Vanguard, Dimensional, iShares dominant in 90%+ of portfolios), with consistent overweight in tech giants (Apple/NVDA/MSFT top holdings across 20+ filers, e.g., $50M+ Apple in several) signaling broad conviction in US equities amid low active management. Q1 2026 earnings mixed: robust growth in Vertiv (+30% YoY sales, +430bps margins), Monarch Casino (+8.9% rev, +38.9% net income), but pressures in Otis (margins -130bps YoY) and Elevance Health (+1.5% rev but -34% op gain, Medicare -15.8% memberships). Financials highlights include Elevance raising FY adj EPS to >=$26.75 with $5.6B buyback auth and $1.72 div, First Northern Nasdaq uplisting Apr24, robust capital returns (Otis $400M repurchases, Monarch $17.6M shares). M&A active with National Healthcare $560M accretive acquisition (Q3 close), SPAC deals/terminations, HIVE $100M notes for capex. Forward guidance mostly raised (Vertiv FY sales +29-31% org, Otis low-mid single digits org), backlog builds (Otis mod +30%), but China weakness and costs persistent. Portfolio-level: avg rev growth ~15% YoY in reporters, margins mixed (-100bps avg compression), strong FCF enabling returns; implications favor resilient growth names amid macro caution.

10 high priority 40 medium 50 total filings